WO2012150818A3 - 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트 - Google Patents

만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트 Download PDF

Info

Publication number
WO2012150818A3
WO2012150818A3 PCT/KR2012/003445 KR2012003445W WO2012150818A3 WO 2012150818 A3 WO2012150818 A3 WO 2012150818A3 KR 2012003445 W KR2012003445 W KR 2012003445W WO 2012150818 A3 WO2012150818 A3 WO 2012150818A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid leukemia
chronic myeloid
risk
present
diagnosis kit
Prior art date
Application number
PCT/KR2012/003445
Other languages
English (en)
French (fr)
Other versions
WO2012150818A9 (ko
WO2012150818A2 (ko
Inventor
김종원
김동환
이승태
원홍희
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Publication of WO2012150818A2 publication Critical patent/WO2012150818A2/ko
Publication of WO2012150818A9 publication Critical patent/WO2012150818A9/ko
Publication of WO2012150818A3 publication Critical patent/WO2012150818A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트 에 관한 것으로서, 구체적으로 본 발명은 MTHFD1L, AKAP12, ZBTB2, RMND1, C6orf211, C6orf97, ESR1, WSB1, FAM27L, FLJ33360, 및 EBF1로 이루어진 군에서 선택되는 하나 이상의 유전자 및 이의 전사조절(transcriptional regulation) 영역에 위치한 단일염기다형성(SNP) 또는 이에 상보적인 서열을 포함하는 만성 골수성 백혈병 진단용 조성물 및 이를 이용하는 진단키트 등에 관한 것이다. 본 발명의 만성 골수성 백혈병과 연관성이 있는 유전자 및 단일염기다형성 마커를 이용하여 만성 골수성 백혈병 발생 위험도를 효과적으로 예측 또는 진단할 수 있다. 나아가 본 발명은 만성 골수성 백혈병의 치료 및 약물 개발 연구에 활용될 수 있다.
PCT/KR2012/003445 2011-05-02 2012-05-02 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트 WO2012150818A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110041690A KR20120124507A (ko) 2011-05-02 2011-05-02 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트
KR10-2011-0041690 2011-05-02

Publications (3)

Publication Number Publication Date
WO2012150818A2 WO2012150818A2 (ko) 2012-11-08
WO2012150818A9 WO2012150818A9 (ko) 2013-02-21
WO2012150818A3 true WO2012150818A3 (ko) 2013-04-11

Family

ID=47108140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003445 WO2012150818A2 (ko) 2011-05-02 2012-05-02 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트

Country Status (2)

Country Link
KR (1) KR20120124507A (ko)
WO (1) WO2012150818A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042137A1 (en) * 2014-09-19 2016-03-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100647806B1 (ko) * 2004-11-30 2006-11-23 경북대학교 산학협력단 한국인의 폐암 발생 위험도를 예측하는 방법 및 이를이용한 진단 키트
US20090208962A1 (en) * 2005-11-29 2009-08-20 Perlegen Sciences, Inc. Markers for breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100647806B1 (ko) * 2004-11-30 2006-11-23 경북대학교 산학협력단 한국인의 폐암 발생 위험도를 예측하는 방법 및 이를이용한 진단 키트
US20090208962A1 (en) * 2005-11-29 2009-08-20 Perlegen Sciences, Inc. Markers for breast cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"myelogenous leukemia: a meta-analysis' Leuk.", LYMPHOMA., vol. 51, no. 7, July 2010 (2010-07-01), pages 1288 - 1292 *
DATABASE NCBI 16 December 2010 (2010-12-16), accession no. s3900024 *
KIM, D. H. ET AL.: "A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia", BLOOD, vol. 117, no. 25, 3 May 2011 (2011-05-03), pages 6906 - 6911 *
KIM, DONG HWAN: "Massive Genome Study for Gene Mining Associated with Chronic Myelogenous Leukemia", MINISTRY OF EDUCATION, SCIENCE AND TECHNOLOGY, FINAL REPORT OF BASIC RESEARCH, 28 February 2011 (2011-02-28), pages 20 - 22 *

Also Published As

Publication number Publication date
WO2012150818A9 (ko) 2013-02-21
WO2012150818A2 (ko) 2012-11-08
KR20120124507A (ko) 2012-11-14

Similar Documents

Publication Publication Date Title
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
CA2812115C (en) Epigenetic markers of colorectal cancers and diagnostic methods using the same
WO2013181125A3 (en) Methods of detecting single nucleotide polymorphisms at codon 600 of human braf
MX2007009809A (es) Amplificacion de sonda por seleccion.
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
WO2009015863A3 (en) Methods of detecting methylated dna at a specific locus
IL200134A0 (en) Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
WO2011116088A3 (en) Compositions and methods for the detection of genomic features
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2012104340A2 (en) Markers of melanoma and uses thereof
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
EP2708607A3 (en) Genetic markers for Myb28
WO2008076856A3 (en) Reagents and methods for detecting cyp2d6 polymorphisms
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
WO2009102748A3 (en) Alternatively transcribed genes associated with schizophrenia
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
MY184632A (en) A method of identifying parentage in freshwater prawn macrobrachium rosenbergii
WO2011020906A3 (en) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2012034013A3 (en) Detection of rna-interacting regions in dna
WO2012150818A3 (ko) 만성 골수성 백혈병 위험도를 예측하는 방법 및 이를 이용한 진단키트
WO2013043041A3 (en) Methods and compositions for diagnosing familial hypercholesterolemia
WO2012034041A3 (en) Detection of chromatin structure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12779701

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12779701

Country of ref document: EP

Kind code of ref document: A2